Metformin: uses, dosing, side effects & brands

RIOMET oral solution contains the biguanidine antihyperglycemic agent metformin in the form of monohydrochloride salt. Metformin hydrochloride, is N , N -dimethylimidodicarbonimidic diamide hydrochloride.

The FDA classifies metformin as a biguanide. If you are checking whether it is safe to combine with something else, the class is what matters — two drugs from the same class usually should not be stacked.

The label's §8.1 Pregnancy Risk Summary states that limited data with metformin in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage, and that published post-marketing studies have not reported a clear association between metformin and major birth defects or miscarriage — though those studies cannot rule out risk because of methodological limitations. It stresses that poorly controlled diabetes in pregnancy itself carries substantial maternal and fetal risk (birth defects, stillbirth, preeclampsia, preterm delivery). The label does not tell patients to start or stop the drug; decisions about diabetes treatment in pregnancy should be made with the prescriber. This is what metformin's FDA label says; whether to use it in pregnancy is your prescriber's decision.

The label does not list weight change as an adverse reaction and does not claim a weight effect. Body weight appears only in the Clinical Studies efficacy tables: in the placebo-controlled monotherapy trial, mean body-weight change at week 29 was -1.4 lbs on metformin vs -2.4 lbs on placebo (no advantage over placebo); a pediatric trial showed -3.3 lbs vs -2.0 lbs on placebo; and metformin arms in other trials ranged from a modest loss (-8.4 lbs in one glyburide-comparison study) to a slight gain (+0.9 lbs). Taken as written, the label does not establish a systematic weight effect.

Yes. The label warns against excessive alcohol intake because alcohol potentiates metformin's effect on lactate metabolism, which can increase the risk of metformin-associated lactic acidosis (the drug's boxed-warning risk). Excessive alcohol intake is listed among the risk factors for lactic acidosis, and both the Warnings/Precautions and Drug Interactions sections instruct that patients be warned against excessive alcohol intake while taking metformin. This is a lactic-acidosis risk, not a disulfiram-like flushing reaction. This is what metformin's FDA label says; alcohol advice depends on your dose and health, so confirm with your pharmacist.

The elimination half-life of metformin is about 6.2 hours (plasma elimination half-life in adults with normal kidney function) — that is how long the body takes to clear half of a dose. Metformin is not metabolized and has no active metabolites, so 6.2 hours reflects the parent drug. The often-cited ~17.6-hour "blood" half-life reflects the drug lingering in red blood cells (distribution), not parent-drug elimination. The half-life is prolonged when kidney function is reduced. Half-life is not the same as how long a drug test can detect the drug, and it varies with age, kidney and liver function.

It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run metformin against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.

We track 7 metformin-containing products in the U.S.: Metformin Hydrochloride, Glucophage, Glucophage XR, Riomet, Fortamet, Glumetza and Riomet ER. They are the same active ingredient; they differ in form, manufacturer, price and FDA recall record.

Across the brands we track, metformin is currently marketed as solution, tablet and tablet, extended release, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.

Yes. Our catalog lists 1 generic metformin product alongside the brand versions. A generic has the same active ingredient and must meet the FDA's bioequivalence standard; it usually costs less. Ask your pharmacist which one your plan covers.

The FDA's Enforcement database lists 3 recall records whose product description mentions metformin. The most recent: Metformin Hydrochloride Extended-Release Tablets 1000mg (Mar 13, 2025). A recall applies to specific lots, not to the drug as a whole — check the record for the affected lot numbers.

Metformin starts lowering blood sugar within a few days, but the full effect on your average blood sugar (A1c) takes weeks to months, and the dose is usually increased slowly to limit stomach upset — which itself tends to settle over the first weeks. It is judged by blood-sugar readings and A1c, not by how you feel.

Alcohol: the FDA label flags alcohol as something to be careful with — see the alcohol section above for what it actually says. Other medicines: we hold source-cited interaction answers for Can you take berberine with metformin?, Can you take magnesium with metformin? and Can you drink alcohol with metformin?. This is what the FDA label and our cited sources say — it is not a complete list. Your pharmacist can check your own combination.

The most common side effects are gastrointestinal. In placebo-controlled trials on the FDA label, diarrhea affected 53% of people, nausea or vomiting 26%, gas (flatulence) 12%, weakness or lack of energy 9%, indigestion 7%, stomach-area discomfort 6%, and headache 6%. MedlinePlus also lists constipation, a metallic or changed sense of taste, flushing of the skin, muscle pain, nail changes and rash. The FDA patient label says these "generally go away after you take the medicine for a while," and that taking each dose with meals helps reduce them. Many people who can't tolerate the regular tablet do better on the extended-release (ER) form. This is not a complete list — report anything that bothers you to your prescriber.

Metformin carries an FDA boxed warning for lactic acidosis — a rare but life-threatening buildup of acid in the blood that is a medical emergency and must be treated in a hospital. The FDA patient label says to stop taking metformin and get medical help right away if you: "feel very weak and tired; have unusual sleepiness or sleep longer than usual; have unusual (not normal) muscle pain; feel cold, especially in your arms and legs; have trouble breathing; feel dizzy or lightheaded; have unexplained stomach or intestinal problems with nausea and vomiting, or diarrhea; have a slow or irregular heartbeat." The label notes onset "is often subtle," so don't wait for symptoms to worsen. Risk is higher with kidney or liver problems, heavy alcohol use, dehydration, contrast-dye imaging, or surgery — tell your doctor you take metformin before any procedure. This is a red-flag list, not the full label.

The best-documented long-term risk is vitamin B12 deficiency. On the FDA label, about 7% of people in 29-week trials dropped to subnormal B12 levels because metformin can interfere with B12 absorption; over years this can contribute to anemia and, if unmanaged, nerve symptoms like numbness or tingling. It is described as "rapidly reversible" with B12 supplementation or stopping the drug. Because of this, the label advises checking blood counts every year and vitamin B12 every 2 to 3 years while on metformin. This monitoring is prescriber-managed — do not stop metformin on your own; ask your doctor about a B12 test if you have persistent tiredness, numbness or tingling.

The stomach side effects usually show up early — often in the first days to weeks after starting or after a dose increase — and they are dose-related, which is why doctors titrate the dose up slowly. The FDA patient label says they "generally go away after you take the medicine for a while," so for most people the diarrhea and nausea ease within the first weeks as the body adjusts. The label also notes side effects can "start later in therapy," so new symptoms after months are worth reporting. Vitamin B12 decline, by contrast, develops gradually over months to years. Tell your prescriber if GI symptoms are severe, don't settle after a few weeks, or return after going away — a lower dose, taking it with food, or switching to extended-release often helps.

Metformin taken by itself rarely causes low blood sugar — the FDA label states it "rarely cause[s] hypoglycemia by [itself]." That's a key difference from sulfonylureas and insulin. The real risk comes when metformin is combined with those other diabetes medicines: the label warns of an increased hypoglycemia risk with insulin or an insulin secretagogue (like a sulfonylurea), and says the dose of those drugs may need to be lowered. Low blood sugar can also happen if you skip meals or drink alcohol. Warning signs to treat promptly include shakiness, sweating, fast heartbeat, hunger, confusion, dizziness and irritability. If you're on metformin alone, hypoglycemia is uncommon — but know the symptoms if you also take insulin or a sulfonylurea.

Glucophage (metformin) is FDA-approved as a first-line medicine for type 2 diabetes. Per its FDA label, it is used as an adjunct to diet and exercise to improve blood sugar control in adults and children 10 years and older with type 2 diabetes, alone or alongside other diabetes medicines including insulin (MedlinePlus). It lowers blood sugar three ways: it reduces the glucose your liver makes, decreases how much glucose you absorb from food, and improves your body's response to insulin (MedlinePlus). Beyond diabetes, doctors also prescribe metformin off-label (not FDA-approved for these uses, but legal and evidence-supported): for prediabetes — it is the only antidiabetic medicine the American Diabetes Association recommends for prediabetes — and for polycystic ovary syndrome (PCOS) and gestational diabetes (StatPearls). These off-label uses are common and clinically accepted, but they are not the same as an FDA approval. Do not start or stop metformin on your own; dosing and suitability depend on your kidney function and other conditions.

No — metformin is not an FDA-approved weight-loss drug, and it should not be thought of as one. Clinical references describe it as essentially weight-neutral, with the potential for only modest weight loss in some people (StatPearls) — not comparable to medicines that are FDA-approved specifically to treat obesity. Any weight change is usually small and is a side effect, not the reason metformin is prescribed. It is sometimes used off-label to counter weight gain caused by antipsychotic medications (StatPearls), which is a different situation from weight loss in the general population. If weight is your main concern, that is a conversation to have with a clinician about options that are actually approved for it — don't obtain or use metformin for weight loss on your own.

Yes, but off-label — metformin is not FDA-approved for polycystic ovary syndrome (PCOS), though it is widely and legitimately prescribed for it (StatPearls). Because many people with PCOS have insulin resistance, metformin is used to help improve insulin sensitivity, and it is sometimes used to support ovulation and menstrual regularity. This is an established off-label use backed by clinical evidence, not an FDA-approved indication, so the exact role and dose should be decided with your doctor rather than self-started.